Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Triple Negative Breast Cancer
Interventions: DRUG: TT-00420
Sponsor: TransThera Sciences (Nanjing), Inc.